Company Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Real-time Euronext Paris 12:35:01 2024-03-28 pm EDT 5-day change 1st Jan Change
2.488 EUR +0.40% Intraday chart for Cellectis S.A. +10.38% -9.99%

Business Summary

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Number of employees: 234

Sales per Business

EUR in Million2021Weight2022Weight Delta
Therapeutics
100.0 %
26 53.0 % 18 100.0 % -28.95%

Sales per region

EUR in Million2021Weight2022Weight Delta
France
100.0 %
26 53.0 % 18 100.0 % -28.95%

Managers

Managers TitleAgeSince
Founder 57 99-12-19
Founder 59 99-12-19
Director of Finance/CFO 47 22-02-09
Chief Tech/Sci/R&D Officer 58 20-07-31
Compliance Officer 55 11-03-31
Chief Tech/Sci/R&D Officer 61 00-12-31
Investor Relations Contact 35 18-06-30
Human Resources Officer 54 20-11-15
Corporate Officer/Principal - 20-07-20
General Counsel 42 07-12-31

Members of the board

Members of the board TitleAgeSince
Chairman 75 20-11-04
Founder 59 99-12-19
Founder 57 99-12-19
Director/Board Member 61 11-10-27
Director/Board Member 69 11-10-27
Director/Board Member 57 22-06-27
Director/Board Member 52 22-06-27
Director/Board Member 63 17-06-28
Director/Board Member - 23-06-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 55,583,768 55,583,768 ( 100.00 %) 0 100.00 %

Shareholders

NameEquities%Valuation
16,000,000 22.30 % 39 M €
Bpifrance Participations SA /PRIVATE EQUITY/
8.186 %
5,873,247 8.186 % 14 M €
2,786,924 3.884 % 7 M €
1,862,016 2.595 % 5 M €
Baillie Gifford & Co.
1.879 %
1,347,970 1.879 % 3 M €
996,034 1.388 % 2 M €
983,035 1.370 % 2 M €
Financière Arbevel SA
0.1533 %
110,000 0.1533 % 270 927 €
Sunny Asset Management SA
0.1185 %
85,000 0.1185 % 209 352 €
Saint Olive Gestion SNC
0.1185 %
85,000 0.1185 % 209 352 €
NameEquities%Valuation
Long Focus Capital Management LLC
6.254 %
4,487,293 6.254 % 12 M €
Capital Research & Management Co. (International Investors)
2.577 %
1,848,804 2.577 % 5 M €
Crédit Suisse Fund Management SA
2.005 %
1,438,255 2.005 % 4 M €
Baillie Gifford & Co.
1.138 %
816,643 1.138 % 2 M €
Principal Global Investors LLC
0.5570 %
399,627 0.5570 % 1 M €
Macquarie Investment Management Business Trust
0.3162 %
226,875 0.3162 % 585 338 €
KBC Asset Management NV
0.2278 %
163,447 0.2278 % 421 693 €
Oppenheimer & Co., Inc.
0.1856 %
133,143 0.1856 % 343 509 €
Jackson National Asset Management LLC
0.1627 %
116,754 0.1627 % 301 225 €
Morgan Stanley & Co. International Plc
0.1062 %
76,225 0.1062 % 196 661 €

Holdings

NameEquities%Valuation
479,264 2.43% 8,358,364 $

Company contact information

Cellectis SA

8, rue de la Croix Jarry

75013, Paris

+33 1 81 69 16 00

http://www.cellectis.com
address Cellectis S.A.(ALCLS)